ArticleJournal of endocrinological investigation2021
Growth hormone deficiency and other endocrinopathies after childhood brain tumors: results from a close follow-up in a cohort of 242 patients.
Article in Journal of endocrinological investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Growth Outcomes and Relapse Risk in Pediatric Medulloblastoma Survivors with and Without Growth Hormone Therapy: A 23-Year Single-Center Cohort Study.Journal of clinical medicine · 2026Article
- The influence of tumor location on the onset of endocrine deficits in pediatric brain tumor survivors.Translational cancer research · 2025Article
- The Impact of Growth Hormone Deficiency on Endothelial Function in Childhood Brain Cancer Survivors.Cancers · 2025Article
- Illuminating the hidden cost: A systematic review of cognitive late effects regarding cancer-related fatigue in treated paediatric brain tumors.Technical innovations & patient support in radiation oncology · 2025Review
- Immune checkpoint inhibitors and endocrinopathies in pediatric brain tumor patients.Journal of pediatric endocrinology & metabolism : JPEM · 2025Article
- Prevalence of growth hormone deficiency in brain tumor survivors: a systematic review and meta-analysis.Endocrine oncology (Bristol, England) · 2025Article
- Drivers Underlying Metastasis and Relapse in Medulloblastoma and Targeting Strategies.Cancers · 2024Review
- Endocrine Disorders in Childhood Brain Tumour Survivors: A Single-Centre Study.Journal of the ASEAN Federation of Endocrine Societies · 2024Article
- Long-Term Endocrinologic Follow-Up of Children with Brain Tumors and Comparison of Growth Hormone Therapy Outcomes: A SingleCenter Experience.Turkish archives of pediatrics · 2023Article
- Growth hormone deficiency in adult survivors of childhood brain tumors treated with radiation.Endocrine connections · 2023Article
- Central precocious puberty in Prader-Willi syndrome: a narrative review.Frontiers in endocrinology · 2023Review
- Endocrine Disorders in Children with Brain Tumors: At Diagnosis, after Surgery, Radiotherapy and Chemotherapy.Children (Basel, Switzerland) · 2022Review
- Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model.Journal of endocrinological investigation · 2022Article
- Approach to the Patient: Management of Pituitary Hormone Replacement Through Transition.The Journal of clinical endocrinology and metabolism · 2022Article
- Baseline and Peak Cortisol Response to the Low-Dose Short Synacthen Test Relates to Indication for Testing, Age, and Sex.Journal of the Endocrine Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBrain tumors are the most common solid tumor in children. The prevalence of survivors from these cancers has been increasing, presenting endocrine sequelae in more than 40% of the cases. Our aim was to characterize the endocrinopathies diagnosed in this population, exploring the outcomes of growth hormone treatment.
methodsWe have performed a retrospective analysis of the survivors that were followed-up through a close protocol at our endocrine late-effects clinic.
results242 survivors, followed during 6.4 (0-23.4) years, were considered. The median age at tumor diagnosis was 6.7 (0-18) years and pilocytic astrocytoma was the most frequent neoplasm (33.5%). The prevalence of endocrinopathies was of 71.5%, with growth hormone deficiency being the most frequent (52.9%). An indirect correlation between the age at the beginning of somatropin and growth velocity in the first year of treatment was observed. Those treated with craniospinal radiotherapy presented a smaller final upper/lower segments ratio comparing with those that only received cranial radiotherapy. However, their final height was not compromised when compared to their family height target. We found pubertal delay in 12%; accelerated/precocious puberty in 13.2%; central and primary hypogonadism in 21.9% and 3.3%, respectively; primary and central hypothyroidism in 23.6% and 14.5%, respectively; thyroid nodules in 7.4%; ACTH deficiency in 10.3% and diabetes insipidus in 12%.
conclusionThis study reveals a higher prevalence of endocrinopathies in brain tumors survivors and explores the influence of craniospinal irradiation in the adult body proportions. It reinforces the importance of routine follow-up among survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.